HOME >> MEDICINE >> NEWS
American Heart Association Comment On New England Journal Of Medicine Report OnCalcium Antagonist Nisoldipine (March 5 issue)

A study in the NEJM titled "The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension," finds an increased risk of fatal and non-fatal heart attacks among individuals taking the calcium antagonist nisoldipine compared to individuals taking enalapril, which is a member of a class of drugs called ACE-inhibitors.

The study provides more evidence that calcium antagonists (preferred term for calcium channel blockers) may pose risks for certain people, including those with diabetes and coronary heart disease. Past studies of short-acting calcium antagonists have also found increased risk of cardiovascular complications. It was thought that the longer-acting drugs did not pose similar risks. However, the current study used a long-acting drug.

Speaking for the American Heart Association, Joseph Izzo, M.D., says "individuals taking calcium antagonists should not panic and stop medication without consulting a physician. However, individuals with both known cardiovascular disease and diabetes may want to talk to their physicians about choosing another type of high blood pressure drug, or to use the calcium antagonist in combination with other agents that are complementary." Izzo is a member of the American Heart Association's Continuing Education Committee.

Calcium antagonists dilate (relax) constricted blood vessels and thus reduce blood pressure. However, this vasodilator action may force the heart to pump harder and may also stimulate stress hormones. This action is the opposite of beta-blockers that limit cardiac output, notes Izzo, professor of medicine and pharmacology at the State University of New York, Buffalo.

The study, by Raymond Estacio, M.D., of the Colorado Prevention Center, Denver, included 470 individuals who had high blood pressure and non-insulin dependent diabetes. The trial compared an ACE-inhibitor with a calcium antagonist in the p
'"/>

Contact: Carole Bullock
caroleb@amhrt.org
214-705-1279
American Heart Association
3-Mar-1998


Page: 1 2

Related medicine news :

1. Consumers with disabilities empowered by American Disabilities Act
2. Definition of persistent vegetative state available from American Academy of Neurology
3. African-American women with endometrial cancer have more aggressive cancer than Caucasian women
4. New colorectal cancer screening recommendations for African Americans
5. American Thoracic Society Journal news tips for March 2005 (second issue)
6. Community care tops medical care at preventing heart disease in black Americans
7. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
8. Obesity among African-American stroke survivors increases risk factors for recurrent stroke
9. Awards & fellowships at the International & American Association for Dental Research General Session
10. American Academy of Neurology presents 57th Annual Meeting in Miami Beach
11. News tips from the 2005, 54th Annual Scientific Sessions of the American College of Cardiology

Post Your Comments:
(Date:7/23/2014)... The routine use of a molecular ... likelihood of performing the correct initial surgery for ... from the University of Pittsburgh Cancer Institute (UPCI), ... at the UPMC/UPCI Multidisciplinary Thyroid Center and other ... getting the correct initial surgery by 30 percent, ...
(Date:7/23/2014)... FL (PRWEB) July 23, 2014 Men ... pay higher premiums for life insurance based on national ... cheap life insurance rates search to its comprehensive tool ... at http://quotespros.com/life-insurance.html . , Providers that are ... selected, sorted and reviewed in one or two clicks. ...
(Date:7/23/2014)... near Sellafield or Dounreay since the 1990s are not ... research published in the British Journal of Cancer ... Research Group at the University of Oxford and from ... among those who were under 25 and living near ... in cancer incidence from 1991-2006 between those living near ...
(Date:7/23/2014)... New York, New York (PRWEB) July 23, 2014 ... that the use of a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ... uterine sarcoma and other cancers throughout a woman’s body, ... on July 22nd in the Journal of the American ... hysterectomy using a power morcellator at 500 U.S. hospitals ...
(Date:7/23/2014)... Asking patients if a suspicious skin lesion is ... spot is likely to be cancerous, according to a ... the Department of Dermatology at Temple University School of ... Dermatology on July 23, 2014, found that nearly ... by itching, while 28.2 percent involve pain. Non-melanoma skin ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
(Date:7/23/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... with respect to its naloxone-based opioid overdose reversal ... has received an additional commitment from the National ... National Institutes of Health ("NIH"), to fund a ...
(Date:7/23/2014)... CITY, Calif. , July 23, 2014  Cardica, Inc. ... release financial results for its fiscal fourth quarter and year ... the markets close. Cardica,s management will host a conference call ... and provide an update on the company,s business. ... August 7, 2014, at 4:30 p.m. Eastern Time via phone, ...
(Date:7/23/2014)... Colo. , July 23 2014 Ampio ... of its new headquarters, manufacturing and research facility: ... CO 80112 Direct: (720) 437-6500 ... labor efficient, pharmaceutical drug manufacturing facility will be fully ... produce the first batches of Ampion TM necessary ...
Breaking Medicine Technology:Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
Cached News: